Celularity Inc. Warrant

Celularity received a Nasdaq notification for not timely filing its Quarterly Report on Form 10-Q for June 30, 2025, potentially risking its listing compliance, with a deadline of September 5, 2025 to submit a compliance plan.

Celularity Inc. has acquired the Rebound product from Sequence LifeScience, Inc., expanding its portfolio of placental-derived advanced biomaterial products. The acquisition is expected to contribute significantly to Celularity's biomaterial sales in the fourth quarter of 2024 and for the full year.